Amgen Boosts Bid for Onyx to $130 a Share

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Have Markets Peaked?: What'd You Miss? (Full Show 04/29)
47:42 - Full episode of "What'd You Miss?" Guests include: Ben Laidler, HSBC Securities global equity strategist, Chris White, Viablemkts chief executive officer, and Meredith Sumpter, Eurasia Group Asia director. (Source: Bloomberg)
  • The Week in Tech From Bloomberg West (04/29)
  • Has Apple's Hot Streak Come to an End?
  • NBC Puts Olympics Video on Snapchat